Hence, our results emphasise the relevance of non-canonical NF-κB activation and ETS1 in glioma progression, thereby highlighting the immense potential of targeting the p52-ETS1 regulatory axis in cancer therapy. The gene discussed is NFKB2; the disease is glioma.